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The differential diagnosis of pleural masses is limited. Asbestos-related disease and
invasive bronchogenic carcinoma make up the majority of cases. The diagnostic yield of
biopsies is low, and invasive procedures are often required to achieve diagnosis. A variety
of imaging techniques are available to help differentiate between benign and malignant
disease to help discern which patients to biopsy. While computed tomography has a
relatively good sensitivity and specificity, magnetic resonance imaging (MRI) and positron
emission tomography (PET) both appear to have higher accuracy. MRI has the added benefit
of being an excellent aid in determining surgical resectability of tumors. MRI and PET are
limited, however, by their cost and availability in certain regions.
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Imaging of pleural masses 329Educational aims To briefly review the differential diagnosis of pleural
masses. To familiarize the reader with the various imaging
modalities available for evaluating pleural-based masses.Figure 1 Chest CT.
Figure 2 Spindle cell tumor, low magnification, S-100 stain.To understand the strengths and weaknesses of each
imaging modality.
Case presentation
A 68-year-old woman with a history of diabetes mellitus and
hypertension presented to our outpatient pulmonary clinic
for evaluation of an abnormal chest computed tomography
(CT). She initially presented to her family practitioner with
complaints of snoring, poor quality sleep, and excessive
daytime sleepiness. A polysomnogram (PSG) done at that
time was negative for obstructive sleep apnea (OSA).
However, significant oxygen desaturation was noted during
sleep, and the patient was placed on nocturnal oxygen. As
part of the work-up to discern the etiology of her nocturnal
desaturations, a chest X-ray revealed a possible right lower-
lobe lung mass. A chest CT was then performed (Figure 1).
Positron emission tomography (PET) was then performed
which showed the mass to be hypermetabolic with a
standardized uptake value (SUV) of 7.7.
Based on the CT findings, the patient was referred to
radiology for a CT-guided biopsy of the mass. Pathology
(Figure 2) revealed bland-appearing spindle cell prolifera-
tion with collagenous stroma. Immunohistochemical stains
were negative for Ki-67 and calretinin. Stains for S-100 were
strongly positive, suggesting a neural-based tumor.
Based on the pathology findings and the patient’s
symptoms, she was referred to thoracic surgery for
consideration of resection of the mass. During the surgery,
the mass was found to originate from the intercostal nerve
between the fifth and sixth ribs in the posterior mediasti-
num. Frozen sections revealed a schwannoma (Figure 3).
Pleural plaques are found in 20–60% of workers exposed to
asbestos, and are the most common cause of pleural
masses.1,2 Localized pleural tumors include lipomas, lipo-
sarcomas, and fibrous tumors of the pleura. These tumors
are rare, often asymptomatic, and usually have a good
prognosis with resection.2 Bronchogenic carcinoma may
invade the pleura; giving an appearance consistent with a
pleural mass. While malignant mesothelioma and metastatic
tumors from other sites usually present as extensive pleural
disease or effusion, they may occasionally present as
discrete pleural masses as well. As in our case, masses in
the posterior mediastinum can masquerade as pleural
masses depending on the imaging modality chosen. There-
fore, it is important to choose the proper imaging modality
to fully evaluate pleural masses.
Chest radiography
Radiography is commonly used as an initial screening test
when evaluating patients with suspected lung disease or
pleural abnormalities. However, conventional radiography is
extremely limited in its ability to differentiate between
benign and malignant pleural processes, as well as pleuralprocesses from parenchymal ones.3 When evaluating for
asbestos-related disease, radiography has a sensitivity of
only 13–53%.4 In addition, differentiating malignant from
benign disease is often difficult using less invasive diagnostic
techniques, such as pleurocentesis or percutaneous pleural
biopsy5; VATS or open thoracotomy is often required. Thus, if
proper imaging can narrow the diagnosis, more invasive
procedures can be avoided in some cases.Computed tomography
When compared to radiography, the use of CT is superior in
differentiating between pleural and parenchymal disease,
determining the location and extent of disease, and can
occasionally allow characterization of tissue based on signal
attenuation.6 In addition, CT is more sensitive in detecting
pleural plaques7 and in detecting chest wall/pleural invasion
ARTICLE IN PRESS
Figure 3 Frozen section of Schwannoma, low magnification,
S-100 stain.
Table 1 Sensitivities and specificities for malignant
disease using CT scan.
Sensitivity
(%)
Specificity
(%)
Pleural rind 41 100
Nodular thickening 51 94
Parietal thickening 41 cm 36 94
Mediastinal pleural disease 56 88
A.S. Bruns, J.G. Mastronarde330by a peripheral tumor8 (although CT is also limited in this
ability, see discussion of CT versus MRI below).
One of the earliest studies investigating the use of CT in
evaluating pleural disease was performed by Leung et al.9
This was a retrospective study evaluating the CT findings in
71 patients with pleural disease who all had definitive
pathologic diagnoses. Several findings were more signifi-
cantly associated with malignant disease than with benign
disease. The results of this study are summarized in Table 1.
In addition, it was noted that pleural calcification was
suggestive of a benign process, seen in 16 of 35 patients with
benign disease, versus three of 39 with malignant disease.
In a more recent investigation of 42 patients with pleural
disease evaluated by CT scanning, mediastinal pleural
involvement and pleural nodularity were again found to be
more common in malignant disease.10 Pleural contour
irregularity and infiltration of the chest wall or diaphragm
were other features more often associated with malignant
disease. Twenty-five of the 27 cases of malignancy had one
or more of these features, versus only two of 15 cases of
benign disease for a sensitivity of 93% and a specificity of
87% for detecting malignant disease.Magnetic resonance imaging (MRI)
A major advantage of using MRI is its superior soft tissue
contrast- and spatial-resolution.11 As a result, MRI is
particularly good at demonstrating infiltration of the chestwall or other adjacent tissues by malignant disease, which
becomes important when determining resectability.11,12 In a
study of 34 patients with pleural lesions evaluated by MRI,
high signal intensity on T2-weighted images was associated
with a specificity of 87%, sensitivity of 100%, and negative
predictive value of 100% in detecting malignant lesions.13
CT versus MRI
Most of the data in the use of MRI concerns its comparison to
CT scanning in the evaluation of pleural masses. Initially,
when CT and MRI were in their youth, a major advantage of
MRI in evaluation of the chest was its ability to image the
body in multiple planes. However, with modern computer
technology and 3D reconstruction, CT is now able to provide
the same information, making MRI less superior in this area.
In the previous study by Falaschi et al.,13 all the patients
enrolled also received a CT scan during the evaluation.
Based on morphologic features alone, six of the 34 lesions
were incorrectly identified using CT. Using these six, MRI was
able to correctly identify all of them using long-TR-weighted
images.
The article by Hierholzer et al.,10 previously mentioned
also compared CT and MRI in the evaluation of pleural
diseases. Using morphologic criteria, the features of
malignant disease were similar to that of CT: mediastinal
pleural involvement, nodularity, contour irregularity, and
infiltration of the chest wall or diaphragm. MRI was able to
discern an additional four cases of chest wall or diaphragm
infiltration over CT, which is important when staging and
determining resectability. When evaluating pleural disease
using signal intensity, 20 of 22 malignant cases demon-
strated signal hyperintensity versus only three of 15 benign
cases. The combination of morphologic criteria and signal
intensity was able to correctly identify all 27 cases of
malignant disease. The overall result revealed MRI as
superior in determining chest wall and diaphragm invasion
with CT being superior in detecting calcification (a marker of
benignity) and bony destruction. CT also has the advantage
of being superior in guidance for biopsy.14
Other studies comparing CT versus MRI have confirmed
the above results and have also shown that MRI is better at
discerning encasement/infiltration of vessels, which is more
important for parenchymal than pleural disease, but gives
further strength to its use in pre-operative evaluation.15
Ultrasound
The use of ultrasound in the evaluation of pleural masses is
limited. While useful due to its relatively low cost, it is
primarily indicated for use as a guidance tool during
drainage of pleural fluid. CT is markedly superior in its
ability to detect pleural thickening and focal masses
compared to ultrasound.9 Currently, ultrasound is not
recommended in the workup of pleural masses.
Positron emission tomography (PET)
PET is a relatively new imaging technique that has been
particularly useful in the evaluation of solitary pulmonary
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Table 2 Summary of various imaging modalities.
Advantages Disadvantages
Plain radiography
Cost; availability Cannot discern malignant
vs. benign disease
Computed tomography
7Cost; guidance for biopsy;
calcification; detection of
plaques
Limited use during
surgical evaluation; lower
sensitivity/specificity
Ultrasonography
Cost; useful for drainage of
effusion
Difficult to visualize
plaques or thickening;
cannot discern malignant
vs. benign disease
Magnetic resonance imaging
Excellent for discerning
tumor respectability; high
specificity/sensitivity
Cost; limited availability
in some areas
Positron emission tomography
High specificity/sensitivity Cost; availability; limited
in use for resectability
Imaging of pleural masses 331nodules for malignant potential as well as for staging of
other malignancies.16,17 A few studies have investigated its
role in the evaluation of pleural masses. In one series of 25
patients, 16 with malignant disease and nine with benign,
PET imaging correctly detected all cases of malignancy, and
seven of the nine cases of benignity.18 An additional study
showed PET imaging as having an accuracy of 92% in
differentiating benign versus malignant disease.19 However,
a large number of the patients in this study had malignant
disease, which may have affected the results.
One of the larger studies evaluating PET imaging involved
92 patients, all of whom had non-small cell lung cancer.20
PET had a sensitivity of 100%, specificity of 71%, PPV of 63%,
and NPV of 100% in diagnosing pleural malignancy. When
combined with CT, specificity rose to 76% and PPV to 67%.
While PET may be useful as a screening tool to decide
when to send a patient for biopsy, it is limited in its ability to
delineate chest wall or diaphragmatic invasion, or to help
determine resectability.
Conclusion
A variety of imaging modalities are currently available for
use in the evaluation of pleural masses. Radiography is
usually a first step, but it is clear that further imaging
beyond this is required. However, further research is
required in order to determine which imaging modality (or
combination of modalities) is the most useful next step prior
to obtaining biopsies. Table 2 provides a summary of the
advantages and disadvantages of the modalities discussed.Conflict of interest statement
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